Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Hepatology. 2014 Nov 25;61(1):200–213. doi: 10.1002/hep.27396

Fig. 4.

Fig. 4

Combined Rapamycin treatment and 4E-BP1A4 transfection completely inhibits AKT/Ras-driven hepatocarcinogenesis. (A) Gross images of livers, (B) liver weight and liver to body weight ratio of AKT/Ras/4EBP1A4 mice treated with vehicle or Rapamycin for 7 weeks. Data are presented as mean ± SEM. **P<0.01. (C) HE images, (D) HA-AKT and (E) p-AKT, p-ERK, p-mTOR staining in Rapamycin-treated AKT/Ras/4EBP1A4 mouse liver. Arrows point to clear-cell hepatocytes. Arrowhead marks weak p-AKT staining in the cytoplasm of a clear-cell hepatocyte. Magnifications: 100× (low magnification of HE and HA); 400× (high magnification of HE, HA, p-AKT; p-ERK, p-mTOR). 148×223mm (300 × 300 DPI)